57054-92-9

Basic information

• Product Name: 5-BROMO-2-CHLORO-4-METHOXYPYRIMIDINE
• Synonyms: 5-BROMO-2-CHLORO-4-METHOXYPYRIMIDINE;Pyrimidine, 5-bromo-2-chloro-4-methoxy-;5-BroMo-2-chloro-4-Methox...;2-chloro-5-broMo-4-MethoxypyriMidine;5-Bromo-2-chloro-4-methoxy-1,3-diazine, 5-Bromo-2-chloropyrimidin-4-yl methyl ether;5-Bromo-2-chloro-4-methoxypyrimidine, >=98%
• CAS NO: 57054-92-9
• Molecular Formula: C₅H₄BrClN₂O
• Molecular Weight: 223.46
• Product Categories: Building Blocks;Pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 57054-92-9.mol
• Article Data: 15

Chemical Properties

• Melting Point: 73-75 °C(Solv: hexane (110-54-3))
• Boiling Point: 323.6 °C at 760 mmHg
• Flash Point: 149.5 °C
• Appearance: /
• Density: 1.745 g/cm³
• Vapor Pressure: 0.00049mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -1.35±0.29(Predicted)
• CAS DataBase Reference: 5-BROMO-2-CHLORO-4-METHOXYPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-CHLORO-4-METHOXYPYRIMIDINE(57054-92-9)
• EPA Substance Registry System: 5-BROMO-2-CHLORO-4-METHOXYPYRIMIDINE(57054-92-9)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 57054-92-9(Hazardous Substances Data)

Usage

Description

5-bromo-2-chloro-4-Methoxypyrimidine is a building block used in the chemical synthesis of halogenated heterocycles.

InChI:InChI=1/C5H4BrClN2O/c1-10-4-3(6)2-8-5(7)9-4/h2H,1H3

Upstream product

• 36082-50-5 2,4-dichloro-5-bromopyrimidine 
• 124-41-4 sodium methylate 

Downstream Products

• 901311-77-1 2-chloro-4-methoxy-5-phenylpyrimidine 
• 901311-78-2 4-methoxy-2,5-diphenylpyrimidine 
• 57054-84-9 (5-bromo-4-methoxy-pyrimidin-2-yl)-dimethyl-amine 
• 6104-41-2 4-methoxypyrimidine 
• 1220417-37-7 (5-bromo-4-methoxy-pyrimidin-2-yl)-(3-chloro-4-fluoro-phenyl)-amine 
• 1229186-56-4 5-bromo-4-methoxy-N-((1R,4R)-4-methylcyclohexyl)pyrimidin-2-amine 
• 1229186-55-3 5-bromo-4-methoxy-N-((1S,4S)-4-methylcyclohexyl)pyrimidin-2-amine 
• 1351343-44-6 [(3R,4S)-4-(2,5-difluoro-phenyl)-1-(5-hydroxy-4-methoxy-pyrimidin-2-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351343-45-7 ((3R,4S)-4-(2,5-difluoro-phenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methoxy-pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351343-43-5 [(3R,4S)-1-(5-bromo-4-methoxy-pyrimidin-2-yl)-4-(2,5-difluoro-phenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351762-22-5 4-(5-bromo-4-methoxypyrimidin-2-ylamino)-3-methoxybenzoic acid 
• 1351759-25-5 C₁₇H₁₉BrN₄O₄ 
• 1443792-51-5 5-bromo-2-iodo-4-methoxypyrimidine 
• 1443792-52-6 tert-butyl (S)-3-(4-(5-bromo-4-methoxypyrimidin-2-yl)phenyl)-2-(4-(tert-butyl)benzamido)propanoate 

Relevant articles and documents

PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS

The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION

The compounds of Formula Ib, Formula Ia, and Formula I are described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The process of preparation of the compounds of Formula Ib, Formula Ia, and Formula I is also described. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are 2-(benzyloxy)pyrimidine derivatives that are inhibitors of PD-1/PD-L1 activation.

GLP-1 RECEPTOR MODULATORS

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "^^^^" represents either or both the R and S form of the compound) (I) where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.